- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07676201
One-year Prognostic Impact of Microcirculation Assessed by NH IMR Angio in Patients Hospitalized for Acute Myocarditis (MICROMYOC)
The goal of this observational study is to evaluate the association between post-coronary angiography IMR and medium-term clinical prognosis in patients with acute myocarditis. The main question it aims to answer is:
Is there a correlation between impaired microcirculation and the occurrence of serious clinical events in this population of patients?
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Male or female patients over the age of 18.
- Patients hospitalized between June 2015 and July 2025.
Patients who presented with chest pain and at least 1 diagnostic criterion; or, in the absence of chest pain, at least 2 of the following diagnostic criteria:
- Electrocardiographic abnormalities (ST-segment elevation or depression, T-wave inversions, conduction disturbances such as type 3 atrioventricular block),
- Elevated troponin levels,
- Abnormal kinematics on echocardiography.
- Associated with MRI findings of ≥2 tissue abnormalities (edema, hyperemia, myocardial fibrosis).
- Coronary angiography performed during the initial hospitalization
- Patient enrolled in or eligible for a social security program.
- Patient who has expressed consent to participate.
Exclusion Criteria:
- Absence of coronary artery disease confirmed by coronary angiography
- Myocarditis secondary to immunotherapy
- Presence of documented coronary artery disease (coronary angiography or cardiac CT)
- Presence of cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy)
- Infiltrative heart disease (sarcoidosis or cardiac amyloidosis)
- Severe valvular heart disease
- Takotsubo syndrome
- Constrictive or chronic pericarditis
- Loeffler's endocarditis
- Left ventricular noncompaction
- Cardiac tumor
- Pulmonary embolism
- Coronary spasm
- Patients covered by Articles L1121-5 through L1121-8 of the Public Health Code (pregnant women, women in labor, and breastfeeding women; persons deprived of their liberty by judicial or administrative decision; adults under guardianship)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
MACE
Délai: From the time of the coronary angiography up to one year
|
The primary endpoint is the 1-year incidence rate of MACE.
MACE is defined by a composite endpoint comprising: 1) all-cause mortality, 2) cardiac decompensation requiring readmission, 3) heart transplantation, 4) documented sustained ventricular arrhythmia lasting >30 seconds, and 5) recurrence of myocarditis.
|
From the time of the coronary angiography up to one year
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Individual components of the 12-month MACE: cardiovascular death, transplantation, hospitalization for heart failure, and persistent heart failure (reported separately)
Délai: From the time of the coronary angiography up to one year
|
From the time of the coronary angiography up to one year
|
|
Correlation between IMR angiographic NH (continuous variable) and: a) MRI imaging criteria (LVEF, fibrosis, septal involvement, edema); b) biological markers (maximum troponin, CRP)
Délai: From the time of the coronary angiography up to one year
|
From the time of the coronary angiography up to one year
|
|
Predictive value of MRI angiography: diagnostic performance in predicting the primary endpoint (ROC, optimal cut-off values, sensitivity/specificity)
Délai: From the time of the coronary angiography up to one year
|
From the time of the coronary angiography up to one year
|
|
Assessment of inter- and intra-observer reproducibility of the MR angiography NH calculation (if a subsample is reanalyzed)
Délai: From the time of the coronary angiography up to one year
|
From the time of the coronary angiography up to one year
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 38RC26.0180
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .